MIST - Milestone Pharmaceuticals Inc.
| Previous Close | 21.20 |
| Open | 21.02 |
| Bid | 20.71 x 800 |
| Ask | 20.99 x 1800 |
| Day's Range | 20.69 - 21.34 |
| 52 Week Range | 12.36 - 27.95 |
| Volume | 78,702 |
| Avg. Volume | 38,634 |
| Market Cap | 535.344M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.79 |
| Earnings Date | Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.63 |
- Simply Wall St.
Here's Why We're Not Too Worried About Milestone Pharmaceuticals's (NASDAQ:MIST) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Barrons.com
Two Small Biotechs See Big Stock Purchases by Their Largest Holders
The stocks of La Jolla Pharmaceutical and Milestone Pharmaceuticals have gained this year as investors buy them up.
- Insider Monkey
Should You Avoid Milestone Pharmaceuticals Inc. (MIST)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
CNW GroupCanadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach
Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach
- CNW Group
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
- CNW Group
Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update
- CNW Group
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
MONTREAL and CHARLOTTE, N.C. , Oct. 3, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Company's open-label, global safety study of etripamil, the Company's novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). "Commencement of enrollment in NODE-303 marks an important step forward for our Phase 3 program of etripamil in PSVT, where current standards of care are restricted to the burdensome and costly acute care setting," said Joseph Oliveto , President and Chief Executive Officer of Milestone Pharmaceuticals.
- CNW Group
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
- CNW Group
Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results
Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results
- Simply Wall St.
Do Institutions Own Shares In Milestone Pharmaceuticals Inc. (NASDAQ:MIST)?
Every investor in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) should be aware of the most powerful shareholder...
- CNW Group
Milestone Pharmaceuticals to Host Mid-Year Update Conference Call
Milestone Pharmaceuticals to Host Mid-Year Update Conference Call
- CNW Group
Milestone Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
Milestone Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
- CNW Group
Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting
Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting
- CNW Group
Milestone Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering
MONTREAL and CHARLOTTE, N.C. , May 14, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the underwriters for its initial public offering of common shares have fully exercised their option to purchase an additional 825,000 common shares at the public offering price of $15.00 per share. The gross proceeds to Milestone from the exercise of the option, are expected to be approximately $12.4 million , bringing the total gross proceeds of Milestone's initial public offering to approximately $94.9 million before deducting underwriting discounts, commissions and offering expenses. All of the common shares were offered by Milestone.
- CNW Group
Milestone Pharmaceuticals Announces Closing of Initial Public Offering
MONTREAL and CHARLOTTE, N.C. , May 13, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the closing of its previously announced initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share. The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, were approximately $82.5 million . All of the common shares were offered by Milestone.
- CNW Group
Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
MONTREAL and CHARLOTTE, N.C. , May 8, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its upsized initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share. The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $82.5 million . All of the common shares are being offered by Milestone. In addition, Milestone has granted certain of the underwriters a 30-day option to purchase up to 825,000 additional common shares at the initial public offering price, less the underwriting discounts and commissions.
